An Efficacy and Safety Study of Tacrolimus Ointment in Adult Participants With Atopic Dermatitis
NCT01828879 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 74
Last updated 2013-04-11
Summary
The purpose of this study is to evaluate the safety and efficacy of tacrolimus ointment in treating the signs and symptoms of moderate (medium level of seriousness) to severe (very serious, life threatening) atopic dermatitis (an intensely pruritic \[itching\], chronic \[lasting a long time\], inflammatory \[pain and swelling\], immunologically based skin disease with a genetic predisposition \[latent susceptibility to disease at the genetic level\]) in adult participants.
Conditions
- Dermatitis, Atopic
Interventions
- DRUG
-
Tacrolimus ointment, 0.1 percent will be applied twice daily, in adult population for 4 weeks or until 1 week after the affected areas defined for treatment at baseline are completely cleared, whichever is first.
Sponsors & Collaborators
-
Janssen-Cilag Ltd.,Thailand
lead INDUSTRY
Principal Investigators
-
Janssen-Cilag Ltd.,Thailand Clinical Trial · Janssen-Cilag Ltd.,Thailand
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2007-11-30
- Primary Completion
- 2009-06-30
- Completion
- 2009-12-31
Countries
- Vietnam
Study Locations
More Related Trials
-
Treatment and Control of Atopic Dermatitis With 0.1% Tacrolimus Ointment
NCT00480610 ·Status: COMPLETED ·Phase: PHASE3
-
Distribution of Tacrolimus in Skin, Atopic Dermatitis
NCT00534508 ·Status: COMPLETED ·Phase: PHASE2
-
Long-term Safety of Protopic in Atopic Eczema
NCT00560378 ·Status: COMPLETED ·Phase: PHASE3
-
Study of the Safety and Efficacy of Tacrolimus Ointment in Treating Chronic Allergic Contact Dermatitis
NCT00667056 ·Status: COMPLETED ·Phase: PHASE4
-
Study to Evaluate the Response to Treatment and Safety of 0.03% Tacrolimus (FK506) Ointment Administered in Pediatric Patients With Moderate to Severe Atopic Dermatitis
NCT00691262 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Aged 2 Years and Older) With Atopic Dermatitis
NCT02118792 ·Status: COMPLETED ·Phase: PHASE3
-
Tacrolimus Ointment Pharmacokinetics in Infants With Atopic Dermatitis
NCT00535691 ·Status: COMPLETED ·Phase: PHASE2
-
Tacrolimus Ointment Long Term Safety in Young Children With Atopic Dermatitis
NCT00560326 ·Status: COMPLETED ·Phase: PHASE2
-
Proactive Treatment of Tacrolimus Ointment for Adult Facial Seborrheic Dermatitis
NCT01591070 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Pediatric Atopic Dermatitis
NCT02748993 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Adults With Atopic Dermatitis
NCT02757729 ·Status: COMPLETED ·Phase: PHASE2
-
Preventive Treatment of Tacrolimus Ointment in Children With Atopic Dermatitis
NCT01745159 ·Status: COMPLETED ·Phase: PHASE4
-
Tacrolimus Versus Hydrocortisone in Atopic Dermatitis
NCT05324618 ·Status: COMPLETED ·Phase: PHASE4
-
Safety, Tolerability, and PK of AN2728 in Adolescents With Atopic Dermatitis
NCT01652885 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Treatment and Control of Atopic Dermatitis With 0.03% Tacrolimus Ointment
NCT00480896 ·Status: COMPLETED ·Phase: PHASE3
-
Pimecrolimus Cream 1% Plus Topical Corticosteroid in Patients (2-17 Years of Age) With Severe Atopic Dermatitis
NCT00121381 ·Status: COMPLETED ·Phase: PHASE4
-
Extended Release Tacrolimus (Advagraf®) in Severe Adult Atopic Dermatitis Patients
NCT01789619 ·Status: COMPLETED
-
Exploratory Study to Evaluate the Application of NLAC Cream in Adults With Atopic Dermatitis
NCT05092464 ·Status: UNKNOWN ·Phase: NA
-
A Study to Explore the Safety, Tolerability, Efficacy, and Pharmacokinetics of LT-002-158 Tablets in Chinese Adult Subjects With Atopic Dermatitis
NCT06931990 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Secukinumab for Treatment of Atopic Dermatitis
NCT02594098 ·Status: COMPLETED ·Phase: PHASE2
-
Comparison of the Efficacy and Safety of Two Topical Creams for Pediatric Atopic Dermatitis
NCT00828412 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis
NCT02118766 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Tolerability Study of Device, RD047-26 for the Treatment of Mild to Moderate Atopic Dermatitis in Adults
NCT01232985 ·Status: COMPLETED ·Phase: PHASE2
-
Study of 0416 Ointment in the Treatment of Atopic Dermatitis
NCT01053247 ·Status: COMPLETED ·Phase: PHASE3
-
Tofacitinib Ointment For Atopic Dermatitis (Atopic Eczema)
NCT02001181 ·Status: COMPLETED ·Phase: PHASE2